coMra Eye Hub

Research Gallery

10 min read

Clinical & Experimental Studies Related to coMra Therapy

Functional Gains in Optic-Nerve Care

This gallery curates clinical studies on low-intensity, non-invasive modalities—laser, magnetic fields, ultrasound, light stimulation—applied on or around the eye or transcranially.

  • We prioritize outcomes that matter to clinicians: visual fields, optic-nerve function, perfusion, and safety.

  • Findings are presented as adjunctive to standard care; no device equivalence is implied.

  • Each digest highlights a clinical takeaway, followed by an expandable section with summary and data/methods.

Use this gallery as a reference hub: a quick way to see that functional vision can be influenced—not only preserved—through carefully applied non-pharmacologic support.

What you’ll notice across studies

  • Fields improve
  • Nerve conduction improves
  • Gains last

Studies at a Glance

  • Egorov 2013 — Infrared laser + weak magnetic field (transcranial) → Expanded fields, improved VEP, better ocular blood flow.
  • Kamenskikh 2012 — Pulsed magnet ± electrostimulation (transcranial/cervical) → Improved perimetry, faster conduction, better hemodynamics.**
  • Baranov 2016 — Laser, magnet, electrostimulation, millimeter-wave (multi-modal) → lasting gains in acuity and fields, confirmed at follow-up.
  • Kamenskikh 2015 — Magnet alone, magnet+electrostim, or magnet at cervical ganglia → Magnet+electrostim gave the strongest functional gains; cervical application the best vascular effects.
  • Sidelnikova 2014 — Infrared laser + weak magnetic field (trabecular target) → Expanded fields, fewer scotomas, better blood flow and lower IOP.
  • Novikova 2011 — Low-intensity ultrasound (bio-regulated) → Superior outflow and optic-nerve support vs conventional ultrasound.

Digest: Egorov 2013 — Transcranial Laser + Magnetic Therapy in Glaucoma

(Click to Expand)

Clinical takeaway: In 165 glaucomatous eyes, combined transcranial low-intensity laser + magnetic therapy (vs magnetic alone) produced larger, more durable gains — expanded visual fields, reduced scotomas, stronger VEPs, and improved ocular blood flow.

Summary:
This study used infrared laser with a weak magnetic field transcranially. Patients showed measurable field enlargement, scotoma reduction, and improved conduction (VEP). Doppler confirmed better ocular blood flow.

Follow-up showed these gains were stable over time, suggesting real physiologic change. Though focused on glaucoma, the mechanisms — conduction and perfusion — are relevant in other optic-nerve compromise.

📂 Expand Data & Methods

Data & Methods

  • Design & Population: 165 eyes with primary open-angle glaucoma (POAG), stages I–III.

  • Intervention:

    • Group 1: Combined transcranial magneto-laser therapy — low-intensity IR laser (wavelength ~0.89 μm, power <10 mW) + weak magnetic field (~30–50 mT), applied bitemporally over visual pathways.
    • Group 2: Magnetic therapy only.

  • Outcomes:

    • Compared to magnetic therapy alone, the combined method led to:
      • Visual fields: Average expansion +56% (range 38–74% by stage), with scotomas disappearing in 58% of cases (vs 22% with magnet alone).
      • Electrophysiology: VEP amplitude rose 30–40%, latency shortened up to 15 ms.
      • Ocular blood flow: Posterior ciliary artery velocity ↑ ~20%; resistance index ↓ ~20–25%.

  • Follow-up: Improvements remained stable at 3–6 months.

Digest: Kamenskikh 2012 — Transcranial Magnetic ± Laser Therapy in POAG with Cerebral Ischemia

(Click to Expand)

Clinical takeaway: In 317 glaucomatous eyes (184 patients) with chronic cerebral ischemia, combined transcranial magnetotherapy with either laser or electrostimulation produced the strongest benefits — wider visual fields, fewer scotomas, stronger VEPs, and better ocular blood flow — compared to magnetotherapy alone.

Summary:
This trial compared three physiotherapy methods in POAG complicated by cerebral ischemia:

  1. Magnet + laser
  2. Magnet + electrostimulation
  3. Magnet at cervical sympathetic ganglia

All groups improved, but Groups 1–2 (laser or ES) showed the most pronounced and consistent gains. Patients demonstrated visual field expansion, scotoma reduction, improved VEP amplitude/latency, and better ocular perfusion. Cognitive measures (memory, anxiety, depression) also improved, reflecting systemic neurovascular effects.

The key point is neurovascular synergy: nerve conduction and blood supply improved together. While tested in POAG, these vascular-driven mechanisms are relevant to other ischemic or neurovascular optic-nerve conditions.

📂 Expand Data & Methods

Data & Methods

  • Design & Population: 184 patients (317 eyes), ages 58–76, stages I–III POAG with chronic cerebral ischemia.
  • Groups:
    • Group 1 (91 eyes): Magnetotherapy + dynamic laser
    • Group 2 (129 eyes): Magnetotherapy + electrostimulation
    • Group 3 (97 eyes): Magnetotherapy to cervical sympathetic ganglia
  • Protocol: Daily, 10 sessions × 20 min

Outcomes:

  • Visual fields: Expanded in all groups; scotomas reduced/disappeared in up to 65% of early-stage cases (Groups 1–2), ~30% in Group 3.
  • Electrophysiology:
    • VEP amplitude ↑ 20–35% (strongest in early POAG, Groups 1–2)
    • VEP latency ↓ ~10%, most consistent in advanced stages
  • Hemodynamics (PSCA):
    • Systolic velocity ↑ 15–32%
    • Diastolic velocity ↑ up to ~80% in some subgroups
    • Resistance index ↓ 10–30%
    • Cognitive/Emotional: Improved memory and sleep; reduced anxiety/depression scores in combined arms

Notes: Combined magnet + laser or electrostimulation gave the most pronounced neurovascular synergy. Cervical magnetotherapy was beneficial but less effective overall.

Digest: Baranov 2016 — Multi-Modal Non-Invasive Stimulation Across Optic-Nerve Disorders

(Click to Expand)

Clinical takeaway: In 443 eyes with partial optic nerve atrophy and 157 eyes with retinal dystrophies, laser, electrostimulation, and millimeter-wave therapy — synchronized to patient biorhythms — produced significant, lasting improvements in acuity and fields, far surpassing results from older, non-synchronized devices, confirmed at long-term follow-up.

Summary:
Across glaucomatous, vascular, traumatic, toxic, and infectious optic-nerve cases, the pattern was consistent: coordinated, low-intensity modalities stabilize and restore function more effectively than traditional methods.

The standout finding is durability: unlike many short-term interventions, these improvements were stable months later. For clinicians, this points to the potential of coordinated, low-intensity modalities to stabilize or even restore optic-nerve function.

📂 Expand Data & Methods

Data & Methods

  • Design & Population: 294 patients (443 eyes) with partial optic nerve atrophy (PONA); 90 patients (157 eyes) with retinal dystrophies (CCRD, PRA).

  • Etiologies: Glaucoma (201 eyes), vascular (88), post-traumatic (62), toxic (19), neuroinfection (9), unidentified (64).

  • Interventions: Biocontrolled therapy using:

    • Electrostimulation (transcutaneous).
    • Laser therapy (low-intensity).
    • Millimeter-wave (MMW) therapy. All synchronized to patient biorhythms (pulse/respiration)

  • Protocol: 10–12 sessions

  • Outcomes:

    • Visual acuity: ↑ 0.07–0.18 in 75–95% of eyes.
    • Visual fields: expanded 27–42° in 82–94%.
    • Follow-up: 40–50% showed further gains months later; control group often declined.
    • Relative efficacy: Gains were 1.5–3.5× greater than with non-synchronized device treatments.

  • Notes: In retinal dystrophies, biocontrolled electrostimulation was most effective (94.7% improved). CCRD and PRA both benefited, with sustained gains up to 12 months.

Digest: Kamenskikh 2015 — Comparative Low-Intensity Device Therapies in Glaucoma

(Click to Expand)

Clinical takeaway: In 634 glaucomatous eyes, transcranial magnetic stimulation — either alone, combined with electrostimulation, or applied to cervical sympathetic ganglia — produced measurable gains in visual fields, stronger VEPs, and improved ocular blood flow.

Summary:
This trial compared three non-invasive regimens:

  1. Magnetotherapy alone
  2. Magnet + electrostimulation
  3. Magnet at cervical sympathetic ganglia

All groups improved, with Group 2 showing the strongest functional and electrophysiological gains, and Group 3 showing the most pronounced vascular improvements. Together, results confirm that magnet-based approaches can improve conduction and perfusion in POAG.

📂 Expand Data & Methods

Data & Methods

  • Design & Population: 397 patients (634 eyes) with POAG, stages I–III.

  • Interventions:

    • Group 1: (182 eyes) Transcranial magnetotherapy
    • Group 2: (258 eyes) Transcranial magnetotherapy + electrostimulation
    • Group 3: (194 eyes) Magnetotherapy of cervical sympathetic ganglia

  • Protocol: 10 daily sessions, 20 min each.

  • Outcomes:

    • Visual fields: Expansion with scotoma reduction in up to 65% of Group 2, ~30% of Group 3
    • Electrophysiology: P100 amplitude ↑ 25–35%; latency ↓ 5–10 ms.
    • Hemodynamics (PSCA):
      • systolic velocity ↑ 15–30%;
      • diastolic velocity ↑ up to ~80%;
      • resistance index ↓ 15–35%.

  • Notes: Group 2 gave the strongest visual/functional gains, while Group 3 gave the greatest vascular improvements.

Digest: Sidelnikova 2014 — Laser‑Magnetic Stimulation in Glaucoma

(Click to Expand)

Clinical takeaway: In 190 glaucomatous eyes (96 treated vs 94 control), low-intensity infrared laser paired with a weak magnetic field, targeted to the trabecular/drainage region, produced expanded fields, reduced scotomas, and improved ciliary artery blood flow and lower IOP.

Summary:
Researchers combined low-intensity infrared laser with a weak magnetic field, targeted dynamically to the trabecular drainage region. This approach produced a dual effect—field expansion, scotoma reduction, improved ocular hemodynamics, better electrophysiology, and lowered intraocular pressure with improved outflow coefficient. Effects were most pronounced in early/moderate POAG and remained stable for 3 months, supporting its role as an adjunct when fields are narrowing despite standard care.

📂 Expand Data & Methods

Data & Methods

  • Design & Population: 126 patients with POAG (190 eyes: 96 treated, 94 controls).
  • Intervention: Dynamic IR laser (850 nm, 3.5 mW) + weak alternating magnetic field (20 mT), directed transpalpebrally at trabecular meshwork.
  • Protocol: 10 daily sessions, 10 minutes each.
  • Outcomes:
    • Visual fields: 52% reduction in scotomas; some absolute → relative.
    • IOP & Outflow: true IOP ↓ 3–5 mmHg; outflow coefficient ↑, esp. Stages I–II.
    • Electrophysiology: VEP amplitude ↑ ~15% (early/moderate); latency ↓ 15% (Stage I).
    • Hemodynamics (SPCA): systolic velocity ↑ ~15%; diastolic ↑ ~20% (early/moderate); resistance index ↓.
  • Notes: Most effective in early/moderate glaucoma; safe, well tolerated; benefits persisted for 3 months.

Digest: Novikova 2011 — Ultrasound Therapy in Glaucoma

(Click to Expand)

Clinical takeaway: In 157 treated vs 49 control eyes, feedback‑guided 9bio-regulated) , low‑intensity ocular ultrasound yielded greater gains in aqueous outflow and optic‑nerve function indices than conventional ultrasound.

Summary: This trial tested low-intensity ocular ultrasound, tuned by physiologic feedback (bio-regulation). Compared with conventional low intensity ultrasound, it yielded bigger improvements in outflow facility, IOP, and optic‑nerve electrophysiology, with advantages persisting at follow‑up (≈6 months in early POAG; ≈4 months in advanced POAG).

For clinicians, this points to ultrasound as a plausible adjunct for outflow and nerve support, beyond diagnostic use.

📂 Expand Data & Methods

Data & Methods

  • Design & Population: 160 patients (206 eyes): 157 bio regulated ultrasound treated, 49 controls (low intensity ultrasound); POAG, stages I–II.

  • Intervention: Low-intensity ocular ultrasound therapy with biocontrol (dose modulation based on physiologic feedback). Comparator: the same ultrasound without feedback.

  • Protocol: 7 sessions, 10 minutes each.

  • Outcomes:

    • Hydrodynamics: significant ↑ in aqueous outflow coefficient.
    • Optic nerve function: improved in ~75% treated vs 40% control.
    • IOP reduction: more pronounced and sustained in treated group.

  • Notes: Bio-regulated ultrasound produced 2–3× greater functional gains than standard ultrasound.

How to Use This Resource

  • For clinicians: Each digest is structured to surface the practical signal (e.g., field expansion, VEP gains, stable follow-up). The deeper methods are here if you want them.
  • For patients: These are research reports, not treatment promises. They show that gentle, low-intensity therapies have been studied in large numbers of eyes with encouraging results.

👉 If you want access to full abstracts, translations, or methodological notes, →📨 email us.

👉 To see how this research connects to real cases in practice, explore the Clinical Case Gallery

👉 Return to Home Page

Links